antidepressants Flashcards

(49 cards)

1
Q

dep theory – monoamine deficit theory

A

○ Deficit in monoamine neurotransmitters (NA and 5HT) cause depression

○ Evidence: reserpine (inhibit NA and 5HT) storage ==> depressed mood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Limitations of theory

A
  • Hypothesis formulated for NA but later emphasis shift from NA –> 5HT
  • Monoamine markers in depressed pt yield inconsistent and equivocal results
  • Inadequate to explain all pharmacological actions in depression
      * Monoamines impt but there are complex interactions with other neurotransmitter systems as well
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

9 classes of antidep

A
  • MAO Ai (reversible)
  • TCA
  • SSRI
  • SNRI
  • NDRI (bupropion)
  • NaSSA (mirtazapine)
  • melatonin receptors (agomelatine)
  • Serotonin antagonist and reuptake inhibitor (trazodone)
  • multimodal serotonergic antidep (vortioxetine)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MAOi eg

A

moclobemide (safest, reversible MAOi-A)

phenelzine (MAO-i A > B)
tranylcypromine (MAO-i A,B)
selegiline (MAOi-B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

types of MAO enzymes

A
  • MAO-A
    □ 5HT broken down mainly by specific enzyme
    □ NA and dopamine
  • MAO-B
    □ NA and dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MAOi/ RIMA MOA

A

incr biological availability of monoamines
* MAO-A, MAO-B preference
□ affects the conc of neurotransmitters recycled from being degraded by MAO

(A: incr for all 5HT,NA,DA)
(B: more specific for NA,DA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

RIMA indication

A
  • depression (reversible , less SE > older gen)
  • social ANX d/o
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ADR for MAOi

A
  • Postural hypotension (DA)
    • Sympathetic block produced by accumulation of dopamine in cervical ganglia (neck)
    • Acts as inhibitory transmitter, not activated quick enough to respond to change in BP
    • HYPERTENSIVE CRISIS (NE)
  • Restlessness and insomnia, ANX, arrhythmia
    • Due to CNS stimulation
  • Serotoninergic function
    • Not combined with other drugs enhancing serotoninergic function (pethidine)
      ○ Hyperexcitability, incr muscular tone
      ○ myoclonus (jerk, involuntary movements)
      ○ Loss of consciousness
      ○ seizure
      (weight gain, sexual dysfuction)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

DFI for MAOi

A
  • Concomitant intake of too high in tyramine (cheese, cured meats, conc yeast pdt)
    ○ NA SE: Acute hypertension, severe throbbing headache, intracranial hemorrhage
    ○ MAOi prevent break down of monoamines (tyramine), excess tyramine = sympathomimetic effect
      - Tyramine uptake by adrenergic terminals, compete with NA for vesicular compartment
      - Incr displacement and release of NA into synapse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

DDI more likely in___ MAOi

A

irreversible, non-selective MAOis > reversible, MAO-A selective (moclobemide)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DDI for MAOi

A

Serotonin syndrome

  • DDI with serotonergic drugs = incr serotoninergic activity
  • Tremor, hyperthermia, CVS collapse
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TCAs MOA

A

1st gen monoamine reuptake inhibitor antidep

2nd gen has milder SE, improved compliance
(nortriptyline > amitriptyline, imipramine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

types of TCAs + eg

A

1) non-selective for SERT/ NET – 5HT, NA
(imipramine, amitriptyline, nortriptyline, Clomipramine)

2) selective for NET – NA
(desipramine)

both on presynapse, feedback inhibition pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

TCA metabolism

A

amitriptyline (3) –> nortriptyline (2 amine)
imipramine (3) –> desipramine (2)

2*: lower anticholinergic, sedation & cardiotoxic SE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TCA indication

A
  • depression
  • Clomipramine (2nd line for OCD)
  • amitriptyline (neuropathic pain, migraine prophy)
  • nortriptyline (neuropathic pain)
    * late preg
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ADR of TCAs

A
  • Sedation
    • H1
    • Tolerance to sedation can develop in 1-2 wks
  • Postural hypotension
    • a1
  • Dry mouth, blurred vision, constipation
    • Parasympathetic effect (M1)
  • 5HT3 block: GIT & sexual dysfunction
  • seizure, QTc prolong (arrhy), weight gain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

DDI w/ TCAs

A

Serotonin syndrome
* DDI with other drugs that incr serotoninergic activity
* Tremor, hyperthermia, CVS collapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SSRI MOA

A
  • Greater 5HT reuptake selectivity than TCAs
  • 50-1000x selectivity for 5HT > NA
    * minimal effect/ reuptake of NE, DA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SSRI eg

A
  • Fluoxetine (50x selective for 5HT) —-> norfluoxetine
  • Citalopram (1000x 5HT selective)/ escitalopram
  • fluvoxamine
  • sertraline
  • paroxetine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

indication of SSRI

A
  • Depression
  • eating d/o: fluoxetine,
  • OCD: fluoxetine, fluvoxamine, sertraline
  • ANX: escitalopram, paroxetine
  • Panic: citalopram, sertraline
  • Sertraline (BF, post MI depression)
21
Q

advantage of SSRI compared to TCAs

A

1) safer in overdose, less SE (better compliance)
a. TCA > MAOi > SSRI (death per px)
2) Better tolerance than TCAs
a. Improved ADR, better compliance
b. lack affinity for (A1: CVS effect)/ (H1: sedation)/ (M1: anticholinergic dry mouth, constipation)

3) Efficacy

22
Q

ADR of SSRI

A
  • Nausea, Insomnia (trough, b. dose)
    * esp fluoxetine
  • headache, transient nervousness (initiation)
  • seizure, bleeding risk, hypoNa (SIADH), EPSE
  • GI & Sexual dysfunction (5HT3)
  • Sedating effect (H1)
23
Q

specific eg of SSRI ADR

A
  • Fluoxetine (4-6hr)
    * norfluoxetine (4-16d) long t1/2, insomia
  • Citalopram / escitalopram
    * QTc prolongation
  • paroxetine
    * MOST anticholinergic, sedate, weight gain, short t1/2, withdrawl sx
24
Q

serotonin syndrome

A

potentiation of action in central and peripheral NS
(serotonergic drug + MAOi/ another serotonergic)

  • neuromuscular hyperactivity
    (ANX, agitation, confusion, clonus, hyperreflexia, muscle rigidity, unexplained FEVER –> CVS collapse)
25
SNRI MOA
* Similar to dual 5HT & NA reuptake inhibition ~ non-selective TCAs * May have additional receptor antagonism * Monoamine reuptake inhibitor (5HT & NA), weak (DA)
26
SNRI eg
Venlafaxine ---> Desvenlafaxine Duloxetine
27
SNRI indication
* Depression * Generalised ANX disorder: venlafaxine, duloxetine * DM neuropathy, stress urinary incontinence, fibromyalgia, chronic MSK pain - Duloxetine structure resembles panadol
28
SNRI specific ADR (5HT3 antagonist, hypoNa, bleed risk, EPSE)
* venlafaxine: incr BP, seizure * duloxetine: urinary hesitation * avoid in hep and renal insuff
29
ADR of SNRI compare to SSRI
* Serotoninergic ADR (similar to SSRI) * Nausea, insomnia, sexual dysfunction * Withdrawal effects more common and stronger than SSRI and TCA
30
NaSSa (tetracyclic) MOA
mirtazapine = Noradrenergic and specific serotonergic antidepressant * NA (a2 autoreceptor) and 5HT2c receptor antagonist * incr NE and 5HT * (and) Antagonist 5HT2,3. H1, M1
31
NaSSa ADR
- H1 receptor (sedation) - A1 (orthostatic hypotension) - Somnolence, incr appetite, weight gain
32
benefits of NaSSa
- Reverse GI and sexual SE of SSRI/ SNRI - used in elderly, less SIADH effect - breastfeeding (risk vs benefits) - fewer DDI (nor primarily CYP)
33
NDRI MOA
bupropion norepinephrine-dopamine reuptake inhibitor * does not inhibit MAO or the reuptake of 5HT * 3 metabolites (inhibit NE)
34
NDRI indications
Depression Smoking cessation (suppress craving)
35
NDRI ADR
- Seizure ++++ - QTc - Insomnia - Psychosis * not for eating d/o (alr at risk of ion imbalance, if on bupropion, can lead to seizure * decr sexual SE of SSRI/ SNRI
36
PK of NDRI
T1/2: 10-21hr Active metabolites (incr alertness, worsen insomnia ON) - Hydroxybupropion - Threohydrobupropion - Eerythrohydrobupropion
37
benefits of NDRI
Decr SE of SSRI/ SNRI Smoking cessation aid obese pts
38
avoid BUP in
* eating d/o * underweight * seizure * tamoxifen therapy (CYP2D6i) * preg
39
melatonin receptor agonist MOA
agomelatine * agonist of melatonin MT1, MT2 receptors * antagonist of 5HT2C receptor (incr release NE, DA)
40
ADR of MRA
Sedation GI Incr LFT (avoid in hep insufficiency) * has less bleeding risk
41
DDI of MRA
fluvoxamine, ciprofloxacin (strong CYP1A2 inhibitors: incr MRA dose)
42
SARI
trazodone * 5-HT2A antagonist/reuptake inhibitors * Blocks reuptake of 5HT * Antagonise 5HT2a, H1, a1 adrenoreceptor
43
indication of SARi
Depression Insomnia (off-label) ***
44
ADR of SARI H1, A1, 5HT3, bleed, SIADH, EPSE
- sedation - orthostatic hypotension - QTc Rare SE: priapism (long erection)
45
SMS MOA
- serotonin multi-modulator and simulator VORTIOXETINE agonist activity 5HT1A partial agonist activity 5HT1B antagonism 5HT1D, 5HT7, 5HT3
46
vortioxetine therapeutic effects
has several identified mechanisms (5HT agonist, partial agonist, antagonist) - further release of 5HT and other neurotransmitters (DA, NE, Ach, H) in brain (prefrontal cortex, hippocampus)
47
vortioxetine ADR (SMS)
pro-cognitive effects - risk of suicidal thoughts or actions - similar as SSRI (hypoNa, GI, sexual, bleeding risk)
48
ketamine MOA
glutamate NMDA receptor antagonist
49
ketamine indication
* rapid onset antidep effect (nasal spray -- tx-resistent dep + SSRI/SNRI) * anesthetic (IV)